🇺🇸 FDA

Company profile · Sponsor

Evofem

Evofem Biosciences

EVFM · NYSE pharma SAN DIEGO, CA, USA
Pipeline
6
Drugs
1
Patents
8

Quick answer

Evofem (EVFM) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker EVFM
Exchange NYSE
Company type pharma
Headquarters SAN DIEGO, CA, USA
SEC CIK 0001618835

Pipeline (6)

Search pipeline →

  1. AMPHORA

    Evofem

    Contraception

    phase 3 small molecule completed

    1 trial

  2. Conceptrol

    Evofem

    Contraception

    phase 3 small molecule completed

    1 trial

  3. EVO100

    Evofem

    Chlamydia Trachomatis Infection

    phase 3 small molecule completed

    1 trial

  4. EVO100

    Evofem

    Sexually Transmitted Diseases

    phase 3 small molecule completed

    1 trial

  5. LIPO-202

    Evofem

    Central Abdominal Bulging

    phase 3 small molecule terminated

    2 trials

  6. Acidform 5 g

    Evofem

    Healthy

    phase 1 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. secnidazole

    SOLOSEC

    ORAL approved

Patents (8)

Search patents →

  1. US 12280037

    Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12172969

    Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11992472

    Compositions and methods for enhancing the efficacy of contraceptive microbicides

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11439610

    Compositions and methods for enhancing the efficacy of contraceptive microbicides

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11419835

    Method of treatment and prevention of bacterial vaginosis

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11337989

    Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10568855

    Compositions and methods for enhancing the efficacy of contraceptive microbicides

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9566232

    Compositions and methods for enhancing the efficacy of contraceptive microbicides

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Evofem?

Evofem (EVFM) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Evofem sponsor?

We track 6 ClinicalTrials.gov-linked programs for Evofem, including AMPHORA and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Evofem company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.